8-K: Cardinal Health Exceeds Expectations, Raises Fiscal Year 2025 Outlook Amid Strong Segment Growth

Cardinal Health reported flat revenue but increased profitability in Q3 FY25, driven by strong performance across all operating segments, leading to an increased fiscal year 2025 outlook.

Summary

• Cardinal Health's Q3 FY25 revenue remained flat at $54.9 billion compared to Q3 FY24, but increased by 19% excluding the impact of a previously communicated customer contract expiration.
• GAAP operating earnings increased to $730 million, with GAAP diluted EPS at $2.10.
• Non-GAAP operating earnings rose by 21% to $807 million, fueled by profit growth across all operating segments.
• Non-GAAP diluted EPS increased by 13% to $2.35.
• The company raised and narrowed its fiscal year 2025 non-GAAP EPS guidance to $8.05-$8.15, up from $7.85-$8.00.
• The Pharmaceutical and Specialty Solutions segment saw relatively flat revenue at $50.4 billion, but revenue increased 20% excluding the customer contract expiration.
• Global Medical Products and Distribution (GMPD) segment revenue increased by 2% to $3.2 billion.
• The 'Other' segment revenue increased by 13% to $1.3 billion.
• For fiscal year 2026, Cardinal Health anticipates double-digit non-GAAP EPS growth.
• The company completed a $375 million accelerated share repurchase program during the third quarter.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong earnings growth and raised guidance, indicating a healthy financial position and positive future prospects for Cardinal Health.

Positives

• Non-GAAP operating earnings increased significantly by 21% to $807 million.
• Non-GAAP diluted EPS increased by 13% to $2.35.
• Fiscal year 2025 non-GAAP EPS guidance was raised and narrowed to $8.05 to $8.15.
• Pharmaceutical and Specialty Solutions segment profit increased 14% to $662 million.
• Global Medical Products and Distribution segment profit increased 77% to $39 million.
• Other segment profit increased 22% to $134 million.
• The company completed a $375 million accelerated share repurchase program during the third quarter.

Negatives

• Revenue was flat at $54.9 billion compared to the same quarter last year.
• The company narrowed outlook for GMPD segment profit to $130 million to $140 million, from $130 million to $150 million previously.

Risks

• The company acknowledges the evolving macro environment conditions and macro uncertainty.
• The company updated its expectations for fiscal 2026 GMPD segment profit, which it now expects to be at least consistent with fiscal 2025 segment profit.
• Risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• The risk that events outside of our control, such as weather or geopolitical events, may impact demand for our products or may cause supply shortages that impact our cost and ability to fulfill customer demand.

Future Outlook

Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026 and expects strong segment profit growth in Pharmaceutical and Specialty Solutions and across its three operating segments reported in Other. The company is updating its expectations for fiscal 2026 GMPD segment profit, which it now expects to be at least consistent with fiscal 2025 segment profit.

Management Comments

• Jason Hollar, CEO of Cardinal Health, stated, 'Our strong momentum continued into our third quarter as our teams ongoing focus on operational execution and value creation led to excellent financial results.'
• Jason Hollar, CEO of Cardinal Health, stated, 'I am delighted to see the broad-based performance, with all five of our operating segments contributing to our strong growth.'
• Jason Hollar, CEO of Cardinal Health, stated, 'We are pleased to raise our fiscal 2025 guidance demonstrating the strength and resilience of Cardinal Health.'

Industry Context

Cardinal Health's performance reflects the ongoing trends in the pharmaceutical distribution and medical products industries, including the importance of specialty pharmaceutical sales, cost optimization, and strategic acquisitions. The expansion of GI Alliance into urology and the acquisition of Advanced Diabetes Supply Group demonstrate a focus on expanding into higher-growth areas.

Comparison to Industry Standards

• Cardinal Health's revenue growth excluding the customer contract expiration is strong compared to competitors such as McKesson and AmerisourceBergen, which have also been navigating changing market dynamics.
• The company's focus on cost optimization and strategic acquisitions aligns with industry trends, as companies seek to improve profitability and expand their service offerings.
• The expansion of GI Alliance into urology is similar to other multi-specialty MSO platforms that are seeking to provide comprehensive care to patients.
• The acquisition of Advanced Diabetes Supply Group is in line with the trend of healthcare companies expanding into the at-home solutions market.

Management Changes

Legal Proceedings

• The document mentions risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders will likely react positively to the increased earnings guidance and share repurchase program.
• Employees may benefit from the company's strong performance and growth opportunities.
• Customers may benefit from the company's focus on innovation and customer-centric solutions.

Next Steps

• The company plans to further discuss its expectations for fiscal 2026 and beyond at its upcoming Investor Day on June 12, 2025.

Key Dates

Keywords

Cardinal Health, financial results, earnings, outlook, pharmaceutical, medical products, distribution, EPS, revenue, segment profit